Back to School: How biopharma can reboot drug development. Access exclusive analysis here
MorphoSys (FSE:MOR) and Novartis (NVS; SWX:NOVN) signed an antibody deal that should fund the biotech's next stages of internal
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury